Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women
Launched by PFIZER'S UPJOHN HAS MERGED WITH MYLAN TO FORM VIATRIS INC. · Sep 1, 2005
Trial Information
Current as of July 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female outpatients 18 years or older.
- • Overactive bladder symptoms (subject-reported) for greater than or equal to 3 months.
- • Currently sexually active with a male partner.
- Exclusion Criteria:
- • Diagnosed or suspected interstitial cystitis, uninvestigated hematuria, urogenital cancer, and interstitial or external radiation to the pelvis or external genitalia or clinically significant bladder outlet obstruction.
- • Symptoms of incontinence being predominately stress urinary incontinence as determined by the investigator.
- • Treated with antimuscarinic/ anticholinergic medication, for any reason including OAB, within the last 3 months or are expected to start therapy during the study treatment period.
- • Any drug for urgency urinary incontinence (UUI) initiated within the past 3 months prior to Visit 1, with the exception of estrogen (topical or systemic) as long as treatment is not initiated within 4 weeks prior to Visit 1 (screening)
About Pfizer's Upjohn Has Merged With Mylan To Form Viatris Inc.
Viatris Inc. is a global healthcare company formed from the merger of Pfizer's Upjohn division and Mylan, dedicated to providing access to high-quality medicines, including generics and specialty pharmaceuticals. With a strong commitment to innovation and patient-centric solutions, Viatris leverages a diverse portfolio and extensive global reach to address the evolving healthcare needs of patients worldwide. The company aims to create sustainable healthcare solutions by combining expertise in pharmaceutical development, manufacturing, and distribution, ultimately enhancing patient outcomes and improving overall health systems.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Winston Salem, North Carolina, United States
Cleveland, Ohio, United States
San Antonio, Texas, United States
San Francisco, California, United States
Miami, Florida, United States
Salt Lake City, Utah, United States
Little Rock, Arkansas, United States
Denver, Colorado, United States
Clearwater, Florida, United States
New Brunswick, New Jersey, United States
Lakewood, Colorado, United States
Berkeley, California, United States
Philadelphia, Pennsylvania, United States
Columbus, Ohio, United States
San Diego, California, United States
South Bend, Indiana, United States
Metairie, Louisiana, United States
Miami, Florida, United States
Phoenix, Arizona, United States
Creve Coeur, Missouri, United States
Farmington, Connecticut, United States
Newburgh, Indiana, United States
Santa Rosa, California, United States
Albuquerque, New Mexico, United States
Berkeley, California, United States
Pembroke Pines, Florida, United States
Alpharetta, Georgia, United States
Columbia, South Carolina, United States
Las Vegas, Nevada, United States
Columbia, Missouri, United States
Baton Rouge, Louisiana, United States
Baltimore, Maryland, United States
Austin, Texas, United States
Bryan, Texas, United States
Baltimore, Maryland, United States
Philadelphia, Pennsylvania, United States
Morgantown, West Virginia, United States
Las Vegas, Nevada, United States
Cincinnati, Ohio, United States
Irving, Texas, United States
Leesburg, Florida, United States
West Palm Beach, Florida, United States
Seattle, Washington, United States
Evansville, Indiana, United States
Chandler, Arizona, United States
Oakland, California, United States
West Hartford, Connecticut, United States
Weston, Florida, United States
Baton Rouge, Louisiana, United States
Saginaw, Michigan, United States
North Las Vegas, Nevada, United States
Olean, New York, United States
New Bern, North Carolina, United States
Gallipolis, Ohio, United States
Allentown, Pennsylvania, United States
Conroe, Texas, United States
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials